NPPA Caps Retail Prices Of 2 Formulations

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 2 formulations under Drugs Prices Control Order (DPCO) – 2013 based on the decision of 86th authority meeting dated April 28, 2021.

The formulations are budesonide tablet and dexamethasone tablet.

The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.

The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.

In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

  • Related Posts

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs